Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 114

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 114
---
psy, idiopathic hypersomnia and ADHD; and |

| ● | the ability of our management team to lead the development of our product candidates, conclude a strategic partnership deal for Mazindol or any of our pipeline compounds. |

These statements are only
current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. We discuss many of these risks in this in greater detail under the heading “Risk Factors” and elsewhere in this
prospectus and the documents incorporated herein by reference. You should not rely upon forward-looking statements as predictions of future
events.

Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as
a result of new information, future events or otherwise, after the date of this prospectus.

<div align='center'>76

USE OF PROCEEDS</div>

Unless otherwise indicated in an accompanying prospectus
supplement, the net proceeds from the sale of securities will be used for general corporate purposes, including research and development
related purposes and for potential acquisitions. Our management will have significant flexibility in applying the net proceeds of this
offering. In addition, while we have not entered into any binding agreements or commitments relating to any significant transaction as
of the date of this prospectus, we may use a portion of the net proceeds to pursue acquisitions, joint ventures and other strategic transactions.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our cash and cash
equivalents and our capitalization as of June 30, 2024:

| ● | On an actual basis; and |

| ● | On a pro forma basis to give effect to the net proceeds 
 to us from:                                             |

(i) the sale of 81,944
Common Shares at a purchase price of $9.60 per share on July 1, 2024 and generated net proceeds of $573,784,

(ii) the reduction of
liabilities of total $10,010,431 as a result of the following changes:

a) Realization
of approximately $2,500,000 of deferred revenue due to termination of a license agreement with Eurofarma Laboratories S.A. on